Infectious Diseases Division

Jason V. Baker, MD, MS

Professor of Medicine, University of Minnesota Medical School

I have been a physician-scientist at Hennepin Healthcare since 2007 and Director of the Infectious Diseases Division since 2018.  I provide infectious diseases consultation and HIV primary care. I was drawn to Hennepin Healthcare for the clinical and research mission, and the opportunity to work alongside talented colleagues. My research program includes pathogenesis-oriented studies and clinical trials that inform the management of infectious diseases.  My HIV research portfolio primarily involves the management of long-term complications of HIV disease, such as cardiovascular disease and risk for heart failure, conducted both locally as well as in South Africa.  My COVID research portfolio includes clinical trials of novel treatments as well as a focus on cardiac complications.  Finally, I direct an international clinical coordinating center within the NIH/NIAID-funded STRIVE (Strategies and Treatments for Respiratory Infections and Viral Emergencies) network, where I also serve as protocol chair for an ongoing trial.

Education and training

• Infectious Diseases Clinical and Research Fellowship, University of Minnesota Medical School, Minneapolis, MN
• Masters of Clinical Research, University of Minnesota Medical School, Minneapolis, MN
• Internal Medicine Internship and Residency, Oregon Health and Science University, Portland, OR
• MD, University of Wisconsin-Madison, Madison, WI
• BS, University of Wisconsin-Madison, Madison, WI

Recent Publications

NIH My Bibliography 

Grants

• 75N91020F00014 (NIAID): Strategies and Treatments for Respiratory & Viral Emergencies (INSIGHT 018); 5/1/2022-6/3/2025; Principal Investigator of Hennepin International Coordinating Center (ICC), and Protocol Chair for STRIVE Trial E-1
• R01-AG077989 (NIA): Optimization of a behavioral intervention to increase physical activity in older adults living with HIV; 9/1/2022-8/31/2027; Multiple Principal Investigator
• R01-HL158756A (NHLBI): Immunologic basis of cardiac disease after severe COVID-19; 4/1/2022-3/31/2026; Multiple Principal Investigator
• R01-HL160437 (NHLBI): Clinical and immunological factors underlying heart failure with preserved ejection fraction among persons living with HIV in South Africa; 9/1/2021-8/31/2025; Multiple Principal Investigator
• UO1-AI136780 (NIAID): An international multicenter, adaptive, randomized double-blind, placebo-controlled trial of the safety, tolerability and efficacy of hyperimmune intravenous immunoglobulin for the treatment of adult outpatients in early stages of COVID-19 (INSIGHT 012 / OTAC); 1/1/2022-12/31-2023; Co-Investigator, Protocol Chair.
• R01 AI147912 (NIAID). Investigation of persistent HIV immune stimulation in lymphoid tissues during therapy as a cause of sustained immune activation. 04/03/2020 – 03/31/2025; co-investigator
• R34 MH116878 (NIMH). PrEP iT! A Pilot Test of a Mobile Peer Support Intervention to Optimize PrEP Adherence and Retention in PrEP Care; 12/1/2018-11/30/2022; Multiple Principal Investigator.
• U01 AI136780 (NIAID): Strategic Timing AntiRetroviral Treatment (START) Trial; 8/1/2017-4/30/2024; Co-investigator.
• R01 AG045032 (NIA): Treatment to Reduce Inflammation and Improve Immune Recovery among Older HIV Patients; 4/1/2014 – 3/31/2020; Principal Investigator.
• R21 HL137435 (NHLBI): The Effects of Age and Treated HIV Infection on Myocardial Disease in South Africa; 1/1/2018 – 12/31/2020; Multiple Principal Investigator
• R01 HL126542 (NHLBI): Targeted anticoagulant therapy to reduce inflammation in treated HIV disease; 9/1/2014-5/31/2019; Multiple Principal Investigator.

Other Key Professional Activities

• Member, U.S. DHHS Panel on Guidelines for the Use of Antiretroviral Agents for Adults and Adolescents Living with HIV.
• Member, U.S. NIH Panel on Coronavirus Disease 2019 (COVID-10) Treatment Guidelines.

Kristina Burrack, PhD

Assistant Professor of Medicine, University of Minnesota Medical School

My long-term research goal is to develop a comprehensive understanding of host-pathogen interactions in order to enhance immunity and limit immune-mediated pathology with an emphasis on investigating infections and improving vaccination strategies against deadly diseases such as malaria and other pathogens of global health importance. Additionally, the knowledge gained from these studies will be applied to improving adoptive cell therapies to treat cancer and limit immune-mediated damage.

Education and training

• Postdoctoral Fellowship, University of Minnesota Medical School, Minneapolis, MN
• PhD, University of Colorado Anschutz Medical Campus, Aurora, CO
• BA, St. Olaf College, Northfield, MN

Recent Publications

NCBI My Bibliography 

Grants

• R01 HD108015-01 (NICHD): Mechanisms of innate immune dysfunction in SIV/malaria co-infection in pregnancy role; 01/2022 – 12/2026; Consultant
• R01 RHL158756A (NHLBI), role: Immunologic basis of cardiac disease after severe COVID-19; 04/2022 – 03/2026; Co-Investigator
• K22 AI143969-01A1 (NIAID): Investigating IL-10-producing suppressive NK cells; 06/2020 – 09/2022; PI
• UL1TR002494 (NCATS): Investigating IL-10-producing natural killer cells and their immune-modulatory functions; 03/2022 – 02/2024; K-R01 Scholar

Caitlin Eccles-Radtke, MD

Associate Professor of Medicine, University of Minnesota Medical School

Medical Director, Infection Prevention, Hennepin Healthcare

I am a board-certified Infectious Disease Specialist with a clinical interest in HIV, General Infectious Diseases, Infection Prevention, Outbreak Management, and Anal Cancer Screening. I love working at Hennepin Healthcare because it is mission-driven and cares for underserved populations.

Education and training

• Infectious Disease Fellowship, University of Minnesota Medical School, Minneapolis, MN
• Internal Medicine Internship and Residency, Hennepin Healthcare, Minneapolis, MN
• MD, Creighton University School of Medicine, Omaha, NE
• BS in Chemistry – Creighton University, Omaha, NE

Recent Publications

1. Eccles-Radtke C, Henry K. Turning the tide against AIDS by preventing new HIV infections initial experience with Minnesota’s first PrEP Clinic. Minn Med. 2015;98(1):45-48
2. Eccles-Radtke C, Rector TS, Cutting A, Drekonja DM. Urinary tract infections in male veterans with human immunodeficiency virus. Open Forum Infect Dis. 2014;1(3):ofu 100

Anne Frosch, MD MPH

Assistant Professor of Medicine, University of Minnesota Medical School

Vaccine Committee Co-chair, Hennepin Healthcare

I am a physician scientist who runs a laboratory that examines adaptive immune responses to vaccines and infection. Our laboratory does this through the recruitment and maintenance of clinical cohorts and advanced immunologic assays that allow us to study specialized immune system cells specific to a pathogen or vaccine.  We have applied these tools in the study of malaria, HIV, COVID-19, and vaccination. Our long-term goal is to understand how unique characteristic of a patient or pathogen shape the immune response and future protection to guide the design of more effective and safe vaccines.

Education and training

• Infectious Disease Fellowship, University of Minnesota Medical School, Minneapolis, MN
• Postdoctoral Fellowship, Center for Vaccine Development, University of Maryland, Baltimore, MD
• MPH, Johns Hopkins University, Baltimore, MD
• MD, Mayo Medical School, Rochester, MN
• BA, Art History and Biological Sciences, Northwestern University, Evanston, IL

Recent Publications

NCBI My Bibliography 

Grants

• K08-AI141761-01A1 (NIH): Memory T follicular helper cell kinetics and localization during recall immune responses to tetanus vaccination; 2019-2024; Principal Investigator
• R01 (NHLBI): Immunologic basis of cardiac disease after severe COVID-19; 2022-2027; Co-investigator
• (CDC): Influenza and Other Viruses in the Acutely Ill (IVY) Network; 2022-present; Co-investigator
• University of Minnesota Masonic Cross Departmental Grant for Children’s Health: Optimizing iron status while minimizing morbidity in HIV-infected Ugandan children; 2016-2018; Co-Principal Investigator
• F32 (NIAID). AI109808-01: The effects of HIV on malaria specific T and B cell responses; 2014-2015; Principal Investigator
• (American Society of Tropical Medicine and Hygiene): Centennial Award

Teaching Activities

My teaching focus is in providing one on one mentorship for physicians and scientists interested in translational research.  Numerous mentees have gone on to obtain PhD’s and faculty positions in biomedical science in the United States and abroad. All of these students and collaborators have significantly shaped our work through their intellect, passion and commitment to research that improves human health.

• Morgan Harris, Scripps Research
• Gayathri Dileepan, Ohio State University
• Eliud Odhiambo, Indiana University
• Oludare Odumade, Harvard Medical School
• Bartholomew Ondigo, Egerton University
• Kristina Burrack, Hennepin Healthcare Research Institute, University of Minnesota

Other Key Professional Activities

With my research and clinical experience in the care of patients with malaria, I have advocated within Hennepin Healthcare Research Institute, Minnesota, and nationally for the availability of medications for the treatment of severe malaria in travelers.  This has included partnering with members of Congress, community members who work with high-risk travelers, and the Minnesota Department of Health to increase access to safe and affordable malaria treatment and prevention.

Frosch AEP, Ahiskali A, John CC. Unaffordable treatment for severe malaria highlights U.S. drug market pitfalls. STAT. June 11, 2021

Frosch AEP. Artesunate versus quinine: Keeping our options open. Clin Infect Dis. 2020; 70(2):288-289.

Frosch AE, Thielen BK, Alpern JD, et al. Antimalarial chemoprophylaxis and treatment in the USA: Limited access and extreme price variability. J Travel Med. 2022;29(4);taab117.

Minnesota Department of Health Malaria Community Advisory Board

Working with CDC and Congress to provide easy access to severe malaria treatment for Minnesotans

William Keith Henry, MD, FACP

Professor of Medicine, University of Minnesota Medical School

My career has been focused on providing HIV care to persons living or at risk for HIV infection regardless of their insurance status. I have worked in public hospital public health clinic settings in Minnesota since establishing the first HIV clinic in the state in 1985. I have also conducted clinical research focusing on antiretroviral therapy since 1986.

Education and training

• American Academy of HIV Medicine, HIV Specialist-certified
• Infectious Disease Fellowship, University of Minnesota Medical School, Minneapolis, MN
• Internal Medicine Residency, Washington University, St Louis, MO
• MD, University of Illinois, Chicago, IL

Publications

View all publications  (Google Scholar Profile)

Grants

• Gilead Sciences, Inc: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Subjects who are Virologically Suppressed; 2017; Principal Investigator
• GlaxoSmithKline: A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Open-label Study Evaluating the Efficacy, Safety and Tolerability of Longacting Cabotegravir Plus Long-acting Rilpiririne Administered Every 8 Weeks or Every 4 Weeks in HIV-1-Infected Adults who are Virologically Suppressed; 2017; Principal Investigator
• Gilead Sciences, Inc:A Phase III, randomized, multicenter, parallel-group non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir plus lamivudine in HIV-1 Infected Adults who are Virologically suppressed; 2017; Principal Investigator
• GlaxoSmithKline: A Phase 3, Randomized, Double-Blind, Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) in HIV-1, Infected Subjects who are Virologically Suppressed; 2016; Principal Investigator
• Gilead Sciences, Inc: A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF;2016; Principal Investigator
• Gilead Sciences, Inc: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen containing Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG//3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed;2016; Principal Investigator
• GSK1265744 (GlaxoSmithKline): A Phase llb Study Evaluating a Long-Acting Intramuscular Regimen of GSK1265744 plus TMC278 for the Maintenance of Virologic Suppression Following an Introduction of Virologic Suppression on an Oral Regimen of GSK1265744 Plus Abacavir/Lamivudine in HIV-1 Infected, Antiretroviral Therapy-Niave Adult Subjects (Protocol #200056);2014; Principal Investigator

Teaching Activities

• Mentoring/Teaching/Supervision of ID fellows in the Positive Care Clinic
• Frequent lecturer on HIV locally and nationally

Other Key Professional Activities

• Medical Director, Clinic 555 (St. Paul Ramsey Department of Public Health STD Clinic)
• Associate Editor-Journal of Acquired Immune Deficiency Syndromes
• Associate Editor- NEJM Journal Watch (AIDS Clinical Care section)
• Reviewer- JAMA, Annals of Internal Medicine, JAIDS, Clinical Infectious Diseases

Amanda Noska, MD, MPH

Assistant Professor of Medicine, University of Minnesota Medical School

Medical Director, Positive Care Clinic, Hennepin Healthcare

I was drawn to Hennepin Healthcare because of the organization’s mission to care for marginalized populations and because of the outstanding caliber of colleagues within this organization. My research interests include clinical pharmaceutical trials for HIV and viral hepatitis B and C. In the past, I’ve also examined factors that influence the quality of care for persons living with HIV, HCV, and/or HBV, those with substance use disorders, homelessness, and/or a history of incarceration. I have been Medical Director of Positive Care at Hennepin Healthcare since January 2022.

Education and training

• Infectious Disease Fellowship, Brown University, Lifespan Hospitals, Providence, RI
• Internal Medicine Internship and Residency, Hennepin County Medical Center, Minneapolis, MN
• MD, University of Minnesota Medical School, Minneapolis, MN
• MPH, University of Minnesota School of Public Health, Minneapolis, MN
• BA, The College of St. Scholastica, Duluth, MN

Recent Publications

PubMed 

Note: Link above brings you to a PubMed search by author name and, as such, may incorrectly contain publications authored by others with a similar name.

Grants

GSK-219288 (GlaxoSmithKline); Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) (B-Well 2); 2023-Present; Principal Investigator

Jessica Oswald, DO

Assistant Professor of Medicine, University of Minnesota Medical School

Associate Program Director, Internal Medicine Residency, Hennepin Healthcare

I am a board-certified infectious diseases physician who joined the division in 2019 after completing my ID fellowship. My clinical interests are focused on providing patient-centered primary care for people living with HIV, the treatment of viral hepatitis, and the management of general infectious disease in the hospital and outpatient setting. I am also interested in medical education and continuing my growth as a clinician-educator.

Education and training

• Infectious Diseases Fellowship, University of Minnesota Medical School, Minneapolis, MN
• Internal Medicine Chief Resident, Cook County Health, Chicago, IL
• Primary Care Internal Medicine Residency, Rush University and Cook County Health, Chicago, IL
• DO, Des Moines University, Des Moines, IA
• BS, Creighton University, Omaha, NE

Teaching Activities

• Associate Program Director, Internal Medicine Residency, Hennepin Healthcare

Other Key Professional Activities

Pharmacy & Therapeutics committee member

Bryan Rock, MD

Associate Professor of Medicine, University of Minnesota Medical School

Co-Director, Antimicrobial Stewardship Program, Hennepin Healthcare

Tuberculosis Consultant, Minnesota Department of Health

Medical Director, Hennepin County Public Health Clinic

I am board-certified in Infectious Diseases and care for patients in the hospital and in the clinic who have general infectious diseases problems. I am also the Medical Director of the Hennepin County Public Health Clinic and a Civil Surgeon who cares for patients with active and inactive tuberculosis, as well as refugees and immigrants needing infectious diseases screening. I am the State Tuberculosis Consultant for the Minnesota Department of Health. I was involved in training future infectious diseases doctors as the Director for the Infectious Diseases Fellowship Program at the University of Minnesota for 10 years. I have a special interest in the diagnosis, treatment, and management of tuberculosis, immigrant and refugee health, and antimicrobial stewardship.

Education and training

• Infectious Diseases Fellowship, University of Minnesota Medical School, Minneapolis, MN
• Internal Medicine Residency, Hennepin Healthcare, Minneapolis, MN
• MD, University of Minnesota Medical School, Minneapolis, MN
• BA, Drake University, Des Moines, IA

Ronald L. Schut, MD

Assistant Professor of Medicine, University of Minnesota Medical School

I am board-certified in internal medicine and infectious diseases. I see patients in the hospital and clinic who have complex infectious disease concerns. I have particular expertise in the management of HIV infection, and working with a multidisciplinary team, strives to help patients attain and maintain long-term good health.

Education and training

• Research Fellow, Psychoneuroimmunology and Substance Abuse, University of Minnesota Medical School, Minneapolis, MN
• Infectious Diseases Fellowship, University of Minnesota Medical School, Minneapolis, MN
• Internal Medicine Chief Resident, Hennepin Healthcare, Minneapolis, MN
• Internal Medicine Residency, Hennepin Healthcare, Minneapolis, MN
• MD, University of Minnesota Medical School, Minneapolis, MN
• BA, Hope College, Holland, MI

Megan Shaughnessy, MD

Assistant Professor of Medicine, University of Minnesota Medical School

Medical Director, International Travel Medicine Clinic, Hennepin Healthcare

Director, International Education, Internal Medicine Residency Program, Hennepin Healthcare

Course Co-Director, Global Health Course, University of Minnesota Medical School

I have been an infectious disease physician at Hennepin Healthcare since March 2014. I am committed to providing high quality medical care to underserved populations, with a particular interest in immigrant and refugee health. I am dedicated to medical education. I am the Director of International Medical Education at Hennepin Healthcare, where I lead the Global Health Pathway for the Internal Medicine Residency Program.

I am also Global Health Faculty at the University of Minnesota and am one of the co-directors for the Global Health Course. My areas of interest include global medicine, tuberculosis, travel medicine, parasitic diseases, and infections in immunocompromised patients. My specific research interest is infections in immunocompromised immigrants.

Education and training

• Infectious Diseases Fellowship, University of Minnesota Medical School, Minneapolis, MN
• Master of Science- Clinical Research, University of Minnesota Medical School, Minneapolis, MN
• Internal Medicine and Pediatrics Internship and Residency, University of Michigan, Ann Arbor, MI
• MD, University of Minnesota, Minneapolis, MN
• BS, Saint Mary’s College, Notre Dame, IN

Recent Publications

NIH My Bibliography 

Grants

• Hennepin Healthcare Seed Grant: Parasitic infections in immunocompromised patients; 06/01/2021 – 6/30/2022; Principal Investigator
• Healthy Foods, Healthy Lives Institute: Prevalence and molecular epidemiology of Clostridium difficile in food and companion animals, retail meats and humans in Minnesota; 2011-2014; Co-investigator
• T32 A1 055433-07: NIH fellow training grant; 2011-2014; Postgraduate fellow

Jenell Stewart, DO, MPH

Assistant Professor of Medicine, University of Minnesota Medical School

I am a board-certified physician providing infectious diseases and HIV specialty care at Hennepin Healthcare (starting 2022) following clinical training and launching my research career at University of Washington. I am researching the prevention of STIs and HIV among women. Over the past decade, I worked in clinics and conducted collaborative research on HIV and sexually transmitted diseases among cisgender women exchanging sex in Callao, Peru; Mombasa, Kenya; Naivasha, Kenya; and Seattle, USA. My current clinical and behavioral research is at the intersection of HIV/STIs, adherence, and gender in two primary areas of research: first, clinical trials of doxycycline post-exposure prophylaxis (dPEP) for prevention of bacterial STIs among cisgender women taking HIV PrEP, and second, community-based care models for women who exchange sex and inject drugs.

Education and training

• Infectious Diseases Fellowship, University of Washington, Seattle, WA
• Global Health Chief Resident, University of Washington, Seattle, WA
• Internal Medicine Internship and Residency, University of Washington, Seattle, WA
• DO, Des Moines University, Des Moines, IA
• MPH, Des Moines University, Des Moines, IA
• BA, St. Olaf College, Northfield, MN

Recent Publications

NCBI My Bibliography 

Grants

• R01 AI145971 Supp (NIAID): Doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections among Kenyan women using HIV pre-exposure prophylaxis (PrEP and dPEP); 09/01/19—07/31/24; Project Director, Co-Investigator
• K23 MH124466 (NIMH): Understanding STI and HIV prevention adherence among Kenyan women; 07/01/20-06/30/25; Principal Investigator
• R34 DA054588-01A1 (NIAID): Combination primary care and prevention services for women who inject drugs and exchange sex in Seattle, Washington; 08/25/22-08/24/25; Multiple Principal Investigator (contact PI)
• INV-017062 (Bill & Melinda Gates Foundation): Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults: An Adaptive Randomized Platform Trial; 04/15/20-04/14/21; Site Principal Investigator
• INV-016204 (Bill and Melinda Gates Foundation): Efficacy of post‐exposure prophylaxis (PEP) to prevent severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection: A open‐label, randomized study of hydroxychloroquine among adults exposed to coronavirus disease (COVID‐19); 03/24/20-09/30/21; Co-Investigator
• T32 AI007044 (NIAID): Host defense training in allergy and infectious diseases. 07/01/18-06/31/20; Trainee, Infectious Diseases Fellow.
• R24 TW007988: Fogarty International Clinical Research Scholars Support Center. 07/01/11-06/31/12; Scholar

Nicholas S. Vogenthaler, MD, MPH

Assistant Professor of Medicine, University of Minnesota Medical School

Director, Positive Care Clinic HIV and Aging Program, Hennepin Healthcare

Medical Director, Red Door Clinic, Hennepin County Public Health Clinic

I am a board-certified infectious disease physician with clinical interests in the management of HIV in vulnerable populations and in HIV and aging. During my career, I have participated in research examining the role of food insecurity in HIV clinical outcomes and assisted in evaluating interventions that may help link hospitalized HIV patients who use substances effectively to outpatient care. I provide oversight of the PCC HIV and Aging Program which was made possible by a generous patient donation from John Mehring and is endowed in his name.

Education and training

• Infectious Diseases Fellowship, Emory University, Atlanta, GA
• MPH, University of California, Berkeley, CA
• Internal Medicine Internship and Residency, University of California, San Francisco, CA
• MD, University of California, San Francisco, CA
• AB, Duke University, Durham, NC

Recent Publications

PubMed

Note: Link above brings you to a PubMed search by author name and, as such, may incorrectly contain publications authored by others with a similar name.

Rebecca Zadroga, MD

Assistant Professor of Medicine, University of Minnesota Medical School

Director, General Infectious Disease Clinic, Hennepin Healthcare

I am an infectious disease physician with active clinical practice in HIV medicine, renal transplant infectious disease, and travel and tropical health.  My research interests include microbiological diagnostics with particular interest in novel blood culture media and culturing techniques.  The application of this research is aimed at exploring the effects on diagnostic and antibiotics stewardship more broadly. I am the former Director of the Antibiotic Stewardship Program at Hennepin Healthcare.

I have outside interests in health economics and policy and the practice of medicine in austere and wilderness environments as I am an avid outdoorswoman and spend time traveling is developing countries.

Education and training

• Infectious Disease Fellowship, University of Minnesota Medical School, Minneapolis, MN
• Internal Medicine Internship and Residency, Hennepin County Medical Center
• MD, Universidad de Ciencias Medicas, San Jose, Costa Rica
• CTrop Med
• DiMM, Wilderness Medical Society
• MSc, Health Economics, Policy and Management, London School of Economics

Recent Publications

My Bibliography - NCBI (nih.gov)

Grants

Accelerate Diagnostics: Randomized Trial of Fast Bacterial Identification and Phenotypic Antimicrobial Susceptibility Testing in Patients with Positive Blood Cultures using the Accelerate Phenotest BC Kit, Performed on the Accelerate Pheno System as Compared with the Verigene BC-GP/GN;  Principal Investigator